Cognition Therapeutics Expands Access Program for Zervimesine
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company focused on innovative treatments for neurodegenerative disorders, has announced a significant advancement in healthcare access for dementia patients. An anonymous donation has allowed for the launch of an expanded access program (EAP) for zervimesine, specifically aimed at individuals diagnosed with dementia with Lewy bodies (DLB).
Transformative Donation for Patients with DLB
This expansive program is made possible thanks to the generosity of a family affected by DLB, highlighting the profound impact of patient experiences on the pursuit of medical advancements. The family’s connection to zervimesine—demonstrated during the Phase 2 SHIMMER study—has fueled their commitment to supporting others facing similar challenges.
Program Details and First Sites
The EAP is set to provide participants with 100 mg of zervimesine daily for one year. The Banner Sun Health Research Institute in Arizona will serve as the first of eight sites participating in this program. Under the leadership of Dr. David Shprecher, a prominent figure in movement disorders, the site is fully equipped to handle the initial patient enrollment.
What to Expect in Treatment
Initially, the program aims to accommodate around 30 patients, allowing them an opportunity to experience potential benefits of zervimesine. Eligible candidates include participants who completed the SHIMMER study, as well as new patients who meet specific criteria for DLB. The treatment period is anticipated to last roughly a year, with the possibility for more patients to be included as resources permit.
The Vision Behind the EAP
Lisa Ricciardi, Cognition Therapeutics' president and CEO, expressed her excitement about the rapid initiation of the EAP. She emphasized the collaborative efforts of the medical professionals involved, including Dr. James Galvin, the lead investigator from the University of Miami. Dr. Galvin’s expertise and dedication to enhancing patient care has been crucial in getting the program off the ground.
About Zervimesine and Its Potential
As zervimesine has not yet received formal approval from regulatory authorities, it is classified as an investigational medication. This means that while its administration could yield promising results, participants must be aware of potential risks associated with its use. The safety and efficacy of zervimesine are still under evaluation, making the EAP a pivotal opportunity for many affected individuals.
Research and Development at Cognition Therapeutics
Cognition Therapeutics is pioneering efforts to develop therapies targeting age-related degenerative disorders of the central nervous system. Their lead candidate, zervimesine (CT1812), is currently being assessed in multiple clinical programs designed to address both dementia with Lewy bodies and Alzheimer’s disease.
Academic and Clinical Collaboration
The dedicated team at Cognition Therapeutics, coupled with the collaboration of distinguished professionals from institutions such as the University of Miami, is integral to advancing this important research. Dr. Galvin’s reflections on the significance of the expanded access program underscore the emotional narratives behind clinical innovations and the relationships fostered in academia and medicine.
Connecting with Cognition Therapeutics
For patients and caregivers looking for more information about the EAP for dementia with Lewy bodies, it is advised to speak with healthcare providers. Treating physicians interested in becoming involved or gaining access for their patients can reach out to Cognition Therapeutics directly via email.
Frequently Asked Questions
What is the purpose of the Expanded Access Program?
The EAP provides access to zervimesine for patients with dementia with Lewy bodies who may benefit from this investigational treatment.
Who can participate in the EAP?
Participants include individuals who have previously been part of the Phase 2 SHIMMER study and new patients diagnosed with mild-to-moderate DLB.
How long will the treatment last?
Participants will receive treatment with zervimesine for approximately one year.
What is zervimesine?
Zervimesine is an investigational drug being studied for its potential benefits in treating neurodegenerative diseases, including DLB and Alzheimer’s disease.
Who should I contact for more information?
Patients and caregivers seeking more information about the EAP can contact their treating physician or reach out to Cognition Therapeutics via email.
